Are Drug Novelty Characteristics Associated With Greater Health Benefits?

A. Alex Levine (), Daniel E. Enright, Katherine A. Clifford, Stacey Kowal and James D. Chambers ()
Additional contact information
A. Alex Levine: Center for the Evaluation of Value and Risk in Health, Tufts Medical Center
Daniel E. Enright: Center for the Evaluation of Value and Risk in Health, Tufts Medical Center
Katherine A. Clifford: Center for the Evaluation of Value and Risk in Health, Tufts Medical Center
Stacey Kowal: Genentech Inc.
James D. Chambers: Center for the Evaluation of Value and Risk in Health, Tufts Medical Center

Applied Health Economics and Health Policy, 2024, vol. 22, issue 6, No 7, 827-832

Abstract: Abstract Objective The aim of this study was to examine the association between characteristics of novel drugs and incremental health gains relative to standard of care, in terms of quality-adjusted life-years (QALYs). Methods This study’s unit of analysis is the drug–indication pair. For pairs approved by the US FDA from 1999 to 2018, we quantified incremental health gains using QALYs from the published literature and characterized each pair’s novelty in terms of a series of six binary (yes/no) characteristics of novel drugs given special consideration by Health Technology Assessment agencies: Novel mechanism of action, Indicated for a rare disease, Indicated for a pediatric population, Treats a serious condition, Offers meaningful improvement over available therapies, and Potential to address unmet clinical needs. We analyzed measures of bivariate association (Mann-Whitney U and Kolmogorov-Smirnov tests) and multivariable regression, accounting for the influence of multiple novelty characteristics simultaneously. Results Our sample of 146 drugs represents 21% of drugs approved the FDA in the time period (1999–2018). Median and mean QALY gains for ‘novel’ drug–indication pairs exceeded corresponding QALY gains for non-novel drug–indication pairs. For most comparisons, the bivariate relationships between QALY gains and novelty characteristics were significant at p

Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40258-024-00910-3 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:aphecp:v:22:y:2024:i:6:d:10.1007_s40258-024-00910-3

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40258

DOI: 10.1007/s40258-024-00910-3

Access Statistics for this article

Applied Health Economics and Health Policy is currently edited by Timothy Wrightson

More articles in Applied Health Economics and Health Policy from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().